Related Experiment Video
Updated: Jul 20, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
[Relationship between anti-tumor effects of melphalan and IFN-gamma]
Mo-lin Li1, Chuan-gang Li, Xiao-hong Shu
1Pathophysiology Department of Dalian Medical University, Dalian 116027, China. molin_li@hotmail.com
Aim:
To investigate the relationship between IFN-gamma and anti-tumor effects of melphalan in vivo.
Methods:
Different gene-type mice (IFN-gamma(+/+), IFN-gamma(+/-) and IFN-gamma(-/-)), which had the same genetic background of C57BL/6, were used in this experiment. Murine lymphoma EL4 cells were inoculated subcutaneously into different gene-type mice simultaneously. Twelve days later, 7.5 mg/kg melphalan was used intraperitoneally to treat all these IFN-gamma(+/+), IFN-gamma(+/-) and IFN-gamma(-/-) tumor-bearing mice. Tumor size was observed and recorded every one to three days in these different gene-type mice subsequently.
Results:
After melphalan (7.5 mg/kg) treatment, tumor size decreased at a similar rate in IFN-gamma(-/-), IFN-gamma(+/-) and IFN-gamma(+/+) mice within the first 3 d. Tumors shrank further or completely disappeared in most of IFN-gamma(+/-) and IFN-gamma(+/+) mice, whereas tumors grew gradually in all IFN-gamma(-/-) mice.
Conclusion:
7.5 mg/kg melphalan has obvious anti-tumor effects on tumor-bearing IFN-gamma(+/+) and IFN-gamma(+/-) mice, but little effects on IFN-gamma(-/-) mice. These data suggest that IFN-gamma is required for the anti-tumor effects of melphalan on tumor-bearing mice in vivo.
Insights
Interferon-gamma (IFN-gamma) is essential for the anti-tumor efficacy of melphalan chemotherapy in mice. Melphalan effectively reduced tumors in mice with IFN-gamma, but not in those lacking it.
Area of Science:
- Immunology
- Cancer Biology
- Pharmacology
Context:
- Melphalan is a chemotherapy drug used to treat various cancers.
- Interferon-gamma (IFN-gamma) is a cytokine involved in immune responses.
- The role of IFN-gamma in mediating the anti-tumor effects of chemotherapy is not fully understood.
Purpose:
- To investigate the relationship between IFN-gamma and the in vivo anti-tumor effects of melphalan.
- To determine if IFN-gamma is required for melphalan's efficacy against murine lymphoma.
Summary:
- Melphalan (7.5 mg/kg) was administered to C57BL/6 mice with varying IFN-gamma gene types (IFN-gamma(+/+), IFN-gamma(+/-), and IFN-gamma(-/-)) bearing EL4 lymphoma tumors.
- While initial tumor size reduction was similar across groups, tumors in IFN-gamma(-/-) mice regrew, whereas tumors in IFN-gamma(+/+) and IFN-gamma(+/-) mice showed significant shrinkage or complete disappearance.
- These findings indicate that IFN-gamma is crucial for melphalan's anti-tumor activity.
Impact:
- This study highlights the critical role of IFN-gamma in chemotherapy response.
- Suggests that targeting or enhancing IFN-gamma pathways could improve melphalan treatment outcomes.
- Provides a basis for further research into immune-mediated chemotherapy effects.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
